Periscope Capital’s AbbVie ABBV Stock Holding History

Periscope Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,351	Closed	-$219K	–	1159
2022 Q1	$219K	Sell	1,351 -420	-24%	-$61K	0.01%	688
2021 Q4	$239K	Buy	+1,771	New	+$209K	0.01%	670
2018 Q3	–	Sell	-5,967	Closed	-$552K	–	170
2018 Q2	$552K	Buy	+5,967	New	+$583K	0.12%	102

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Periscope Capital's ABBV Position: Q2 2022 in Review

Periscope Capital sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,351 shares — an estimated $219K sold.

Periscope Capital first reported a position in ABBV in Q2 2018 and held it in 3 quarters. The position peaked at $552K in Q2 2018. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Periscope Capital reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Periscope Capital sold 1,351 AbbVie shares in Q2 2022, an estimated $219K.
Periscope Capital first reported a position in AbbVie in Q2 2018 and held it in 3 quarters.
Periscope Capital's AbbVie position peaked at $552K in Q2 2018.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Periscope Capital's 13F filing for Q2 2022, filed 15 Aug 2022.